Linked Life Data

7902875

Source:http://linkedlifedata.com/resource/pubmed/id/7902875

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1994-1-7
pubmed:abstractText
Terazosin was evaluated in 21 normotensive spinal cord injured patients with autonomic dysreflexia. The patients were followed for 3 months during which the autonomic dysreflexia severity and frequency were evaluated. Autonomic dysreflexia severity mean score was significantly improved when measured at baseline and at 1 week, 1 month and 3 months (10.3 +/- 4.2, 5.08 +/- 2.3, 3.83 +/- 2.5 and 4.5 +/- 1.4, respectively, p < 0.0005). No statistically significant change was seen in erectile function and blood pressure. Three patients complained of fatigue, 1 of whom had the dosage reduced from 5 to 2.5 mg. daily. Terazosin appears to be effective in preventing serious harm from autonomic dysreflexia without erectile function impairment. The effectiveness is significant in the first week and remains for at least 3 months.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0022-5347
pubmed:author
pubmed:issnType
Print
pubmed:volume
151
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
111-3
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
Prospective evaluation of terazosin for the treatment of autonomic dysreflexia.
pubmed:affiliation
Department of Urology, Magee Rehabilitation Hospital, Jefferson Medical College, Philadelphia, Pennslyvania.
pubmed:publicationType
Journal Article